Myriad Genetics Inc. (Nasdaq: MYGN) warned that 2009 revenue from its molecular diagnostics unit will fall short. Analysts downgraded the company sending the stock price plunging $9.53 to $26.12.
Myriad Genetics Warns Of Revenue Shortfall
July 01, 2009 at 11:47 AM EDT
